On October 10, 2024, PainReform Ltd. appointed Eyal Broder as Interim Chief Financial Officer, succeeding Dr. Ehud Geller. The company regained compliance with Nasdaq requirements as of December 4, 2024, after previously being notified of non-compliance due to share price issues.